HAIXI PHARMA (02637) announced its performance in 2025, with a net profit of approximately 177 million yuan, a year-on-year increase of 30.09%.

HAIXI PHARMA (02637) announced its performance forecast for 2025, with revenue of approximately 582 million yuan, a year-on-year increase of 24.79%; net profit of approximately 177 million yuan, a year-on-year increase of 30.09%; earnings per share of 2.55 yuan. The announcement stated that the increase in revenue was mainly attributed to the group's strengthened marketing efforts throughout the year, driving the growth of sales revenue for Haihuitong and Anbil. In particular, Haihuitong was newly selected for the national VBP program specification (5mg/20mg14 tablets) in 2025, effectively promoting the expansion of hospital channels and sales growth in the end market.